← Leaderboards
Patrick Beardsley
Virginia Commonwealth University
$12,638,175
Attributed
$12,638,175
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2012–22$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,638,175 · 4
By mechanism
N01$12,638,175 · 4
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Frederick Gerard Moeller$65,095,599
- Richard A Glennon$4,822,005
- Mohamad Imad Damaj$10,091,132
- Mary E Abood$7,791,067
- Hamid I Akbarali$10,975,843
Others in their field
Top investigators on “Contracts”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,154,975,474
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
ContractsPharmaceutical PreparationsIn VivoProgramsRodentAddictionNational Institute Of Drug AbusePharmacotherapyEvaluationRattusRelapseAnimal ModelProtocols DocumentationCocaine Relapse PreventionMethod DevelopmentDrug Of AbuseOpioidPreclinical SafetyClinical TrialsDrug AddictionDrug AbuseCuesAnimalsPharmacologic Substance
Grant awards (13)
MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2019-7/9/2020. N01DA-19-8949$1,202,763
N01 · FY2022 · DA · contact PI
POP: 2/22/17-2/21/21. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932. PURPOSE: TO EXERCISE OPTION QUANTITY 1(CO$968,474
N01 · FY2020 · DA · contact PI
MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2019-7/9/2020. N01DA-19-8949$1,145,375
N01 · FY2019 · DA · contact PI
IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.$989,205
N01 · FY2019 · DA · contact PI
IGF::OT::IGF Medication Discovery Using Rat Models of Relapse; POP 8/29/2014-7/9/2019; FY16 N01DA-14-8917$1,024,658
N01 · FY2018 · DA · contact PI
IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.$886,385
N01 · FY2018 · DA · contact PI
IGF::OT::IGF Medication Discovery Using Rat Models of Relapse; POP 8/29/2014-7/9/2017; FY16 N01DA-14-8917$960,399
N01 · FY2017 · DA · contact PI
IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.$856,466
N01 · FY2017 · DA · contact PI
IGF::OT::IGF Medication Discovery Using Rat Models of Relapse; POP 8/29/2014-7/9/2017; FY16 N01DA-14-8917$1,021,163
N01 · FY2016 · DA · contact PI
IGF::OT::IGF MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE; POP 8/29/2014 - 7/9/2015; FY14 N01DA-14-8917$899,400
N01 · FY2015 · DA · contact PI
IGF::OT::IGF MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE; POP 8/29/2014 - 7/9/2015; FY14 N01DA-14-8917$899,400
N01 · FY2014 · DA · contact PI
MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE$897,035
N01 · FY2013 · DA · contact PI
MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE$887,452
N01 · FY2012 · DA · contact PI